Ex-Dez­i­ma CEO co-founds NASH start­up, fly­ing in­to Phase IIB with €25 mil­lion

A new Dutch biotech, co-found­ed and led by the for­mer CEO of Dez­i­ma, is launch­ing with €25 mil­lion in start­up cap­i­tal from promi­nent Eu­ro­pean in­vestors to de­vel­op an oral drug for NASH.

The Se­ries A round was led by For­bion and BGV, with No­vo Seeds and New Sci­ence Ven­tures join­ing in.

The com­pa­ny, North­Sea Ther­a­peu­tics or NST, is de­vel­op­ing a struc­tural­ly-en­gi­neered fat­ty acid called icos­abu­tate. Since the drug can­di­date has al­ready proven to be safe and ef­fec­tive in two past Phase II clin­i­cal tri­als for hy­per­triglyc­eridemia, NST is fly­ing straight in­to Phase IIb tri­als in NASH.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER